
Opinion|Videos|March 13, 2025
Sequencing Between Available Therapies
Panelists discuss how the optimal sequencing between available therapies for advanced gastric cancer remains challenging but should be guided by patient-specific factors, prior treatment response, and molecular characteristics of the tumor.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
4
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
5



















